Lilly Gains Approval for Zepbound in Sleep Apnea Care
Eli Lilly has achieved a monumental medical advancement through ZEPBOUND (tirzepatide), establishing revolutionary benchmarks within sleep disorder clinical practice. The historic FDA approves ZEPBOUND for obstructive sleep apnea authorization in December 2024 introduces the first pharmaceutical solution specifically developed to address this challenging sleep-related respiratory condition....
0 Comments 0 Shares 1K Views 0 Reviews
Sponsored

Trade with the best

aking Exness the first name that comes to mind when people think about brokers or trading. We’re putting our traders first, not only with trading conditions, but also with the overall...

Sponsored